![](/img/cover-not-exists.png)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
von Bubnoff, Nikolas, Ihorst, Gabriele, Grishina, Olga, Röthling, Nadine, Bertz, Hartmut, Duyster, Justus, Finke, Jürgen, Zeiser, RobertVolume:
18
Language:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-018-5045-7
Date:
December, 2018
File:
PDF, 1.02 MB
english, 2018